Fig. 1From: Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort studyThe frequencies of patients with ≥50% response rate at the last month of therapy with mAbs anti-CGRP pathway and at the three-months of discontinuation in CM and HFEMBack to article page